Repurposing AGI-6780 to Activate ClpP and Target Gram-Positive Bacteria

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• The rise of antibiotic-resistant pathogens necessitates novel antimicrobial strategies.
• Traditional antibiotics targeting essential bacterial processes are facing declining efficacy.
• There is an urgent need for new antimicrobial agents with novel mechanisms of action.

Purpose of the Study:

• To identify small molecules that hyperactivate the bacterial ClpP protease as a novel antimicrobial strategy.
• To discover compounds that induce uncontrolled proteolysis leading to bacterial cell death.
• To explore ClpP as an unconventional target for antimicrobial drug development.

Main Methods:

• High-throughput in silico screening based on known ClpP-binding interactions.
• Molecular docking simulations to predict binding affinity and prioritize compounds.
• In vitro assays to evaluate antimicrobial activity and cytotoxicity.
• Pharmacokinetic profiling of lead compounds.

Main Results:

• AGI-6780 identified as a lead compound with high predicted affinity for the ClpP active site.
• In vitro assays confirmed AGI-6780's efficacy against Gram-positive bacteria by targeting ClpP.
• AGI-6780 demonstrated synergy with rifampicin and minimal cytotoxicity to human cell lines.

Conclusions:

• AGI-6780 is a promising antimicrobial agent that uniquely targets the bacterial ClpP protease.
• Exploiting ClpP offers a novel mechanism to combat antibiotic-resistant pathogens.
• This approach represents a potential new avenue for developing effective antimicrobial therapies.